{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T20:53:06Z","timestamp":1775595186664,"version":"3.50.1"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012986","name":"Universidad Francisco de Vitoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012986","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.yebeh.2020.107540","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T21:34:36Z","timestamp":1606167276000},"page":"107540","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"PA","title":["Initiating antiepilepsy treatment: An update of expert consensus in Spain"],"prefix":"10.1016","volume":"114","author":[{"given":"Vicente","family":"Villanueva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"S\u00e1nchez-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9347-275X","authenticated-orcid":false,"given":"Mar","family":"Carre\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Salas-Puig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Caballero-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Gil-Nagel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2020.107540_b0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neurol.2015.11.003","article-title":"Epidemiology of epilepsy","volume":"172","author":"Behr","year":"2016","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.yebeh.2020.107540_b0010","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/602710","article-title":"Adult prevalence of epilepsy in spain: epiberia, a population-based study","volume":"2015","author":"Serrano-Castro","year":"2015","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.yebeh.2020.107540_b0015","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE official report: a practical clinical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107540_b0020","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.seizure.2017.04.008","article-title":"The debate: treatment after the first seizure-The PRO","volume":"49","author":"Olmes","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2020.107540_b0025","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/epi.16439","article-title":"Treatment initiation decisions in newly diagnosed epilepsy-A longitudinal cohort study","volume":"61","author":"Sharma","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107540_b0030","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.yebeh.2010.07.016","article-title":"Treatment initiation in epilepsy: an expert consensus in Spain","volume":"19","author":"Villanueva","year":"2010","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107540_b0035","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1684\/epd.2019.1083","article-title":"Antiepileptic drugs: evolution of our knowledge and changes in drug trials","volume":"21","author":"Perucca","year":"2019","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2020.107540_b0040","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1006\/ebeh.2001.0283","article-title":"The expert consensus guideline series: treatment of epilepsy","volume":"2","author":"Karceski","year":"2001","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107540_b0045","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1684\/j.1950-6945.2004.tb00074.x","article-title":"The choice of antiepileptic drugs in newly diagnosed epilepsy: a national French survey","volume":"6","author":"Semah","year":"2004","journal-title":"Epileptic Disord"},{"issue":"Suppl 1","key":"10.1016\/j.yebeh.2020.107540_b0050","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.yebeh.2005.06.001","article-title":"Treatment of epilepsy in adults: expert opinion, 2005","volume":"7","author":"Karceski","year":"2005","journal-title":"Epilepsy Behav"},{"issue":"Suppl 1","key":"10.1016\/j.yebeh.2020.107540_b0055","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1177\/088307380502000101","article-title":"Treatment of pediatric epilepsy: expert opinion, 2005","volume":"20","author":"Wheless","year":"2005","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2020.107540_b0060","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1684\/epd.2007.0144","article-title":"Treatment of pediatric epilepsy: European expert opinion, 2007","volume":"9","author":"Wheless","year":"2007","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2020.107540_b0065","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1600-0404.2009.01182.x","article-title":"Opinion of Belgian neurologists on antiepileptic drug treatment in 2006: Belgian study on epilepsy treatment (BESET-2)","volume":"120","author":"Legros","year":"2009","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2020.107540_b0070","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.yebeh.2011.10.018","article-title":"Treatment of epilepsy in adults: expert opinion in China","volume":"23","author":"Yu","year":"2012","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107540_b0075","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.yebeh.2016.11.018","article-title":"Epilepsy treatment in adults and adolescents: expert opinion, 2016","volume":"69","author":"Shih","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107540_b0080","unstructured":"NC D. The Delphi Method: an experimental study of group opinion. Santa Monica, CA: Rand Corp.; 1969. Publication RM-59999-PR. 1969."},{"key":"10.1016\/j.yebeh.2020.107540_b0085","series-title":"The Delphi method: III: Use of self-ratings to improve group estimates","author":"Dalkey","year":"1969"},{"key":"10.1016\/j.yebeh.2020.107540_b0090","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1214\/aoms\/1177705148","article-title":"Snowball sampling","volume":"32","author":"Goodman","year":"1961","journal-title":"Ann Math Stat"},{"key":"10.1016\/j.yebeh.2020.107540_b0095","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1017\/S0266462300002774","article-title":"A method for the detailed assessment of the appropriateness of medical technologies","volume":"2","author":"Brook","year":"1986","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.yebeh.2020.107540_b0100","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-2288-7-52","article-title":"An exploration of the use of simple statistics to measure consensus and stability in Delphi studies","volume":"7","author":"Holey","year":"2007","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.yebeh.2020.107540_b0105","series-title":"The RAND\/UCLA appropriateness method user\u2019s manual","author":"Fitch","year":"2001"},{"key":"10.1016\/j.yebeh.2020.107540_b0110","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1001\/jama.2016.12047","article-title":"Management of an unprovoked first seizure in adults","volume":"316","author":"Tao","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.yebeh.2020.107540_b0115","doi-asserted-by":"crossref","first-page":"e1429","DOI":"10.1212\/WNL.0000000000006319","article-title":"Antiepileptic drug treatment after an unprovoked first seizure: a decision analysis","volume":"91","author":"Bao","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2020.107540_b0120","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.eplepsyres.2013.08.009","article-title":"First seizure in the older patient: clinical features and prognosis","volume":"107","author":"Lawn","year":"2013","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2020.107540_b0125","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1212\/WNL.62.5_suppl_2.S24","article-title":"Special considerations in treating the elderly patient with epilepsy","volume":"62","author":"Ramsay","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2020.107540_b0130","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1016\/S0140-6736(05)66674-3","article-title":"Treatment of new-onset epilepsy: seizures beget discussion","volume":"365","author":"McIntosh","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2020.107540_b0135","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1111\/epi.13093","article-title":"Is the first seizure epilepsy\u2013and when?","volume":"56","author":"Lawn","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107540_b0140","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11940-018-0525-2","article-title":"Acute symptomatic seizures and provoked seizures: to treat or not to treat?","volume":"20","author":"Gunawardane","year":"2018","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.yebeh.2020.107540_b0145","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/ane.13169","article-title":"Consensus statement for the management of generalized tonic-clonic seizures in Spain","volume":"141","author":"Gil-Nagel","year":"2020","journal-title":"Acta Neurol Scand"},{"issue":"Suppl 1","key":"10.1016\/j.yebeh.2020.107540_b0150","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1528-1167.2008.01444.x","article-title":"Risk of recurrence after a first unprovoked seizure","volume":"49","author":"Berg","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107540_b0155","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/epi.14596","article-title":"The epidemiology of drug-resistant epilepsy: a systematic review and meta-analysis","volume":"59","author":"Kalilani","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107540_b0160","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","article-title":"Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry","volume":"17","author":"Tomson","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2020.107540_b0165","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1111\/epi.13702","article-title":"Resistance to valproic acid as predictor of treatment resistance in genetic generalized epilepsies","volume":"58","author":"Gesche","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107540_b0170","first-page":"Fc01-4","article-title":"Valproic acid versus lamotrigine as first-line monotherapy in newly diagnosed idiopathic generalized tonic -clonic seizures in adults - a randomized controlled trial","volume":"10","author":"Giri","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.yebeh.2020.107540_b0175","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/epi.12028","article-title":"Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107540_b0180","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/jnnp-2011-300376","article-title":"KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy","volume":"84","author":"Trinka","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2020.107540_b0185","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.seizure.2005.09.011","article-title":"The LAM-SAFE Study: lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults","volume":"14","author":"Steinhoff","year":"2005","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2020.107540_b0190","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2020.107540_b0195","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1684\/epd.2009.0239","article-title":"Efficacy and tolerability of zonisamide in idiopathic generalized epilepsy","volume":"11","author":"Marinas","year":"2009","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2020.107540_b0200","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamaneurol.2015.4515","article-title":"Efforts in epilepsy prevention in the last 40 years: lessons from a large nationwide study","volume":"73","author":"Sillanp\u00e4\u00e4","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2020.107540_b0205","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/epi.12926","article-title":"A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy","volume":"56","author":"Werhahn","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107540_b0210","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1212\/01.WNL.0000167384.68207.3E","article-title":"New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine","volume":"64","author":"Rowan","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2020.107540_b0215","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1111\/bcp.13653","article-title":"New-onset epilepsy in the elderly","volume":"84","author":"Vu","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2020.107540_b0220","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.yebeh.2019.05.003","article-title":"MONOZEB: Long-term observational study of eslicarbazepine acetate monotherapy","volume":"97","author":"Villanueva","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107540_b0225","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.yebeh.2019.02.022","article-title":"Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: a retrospective study","volume":"94","author":"Del Bianco","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107540_b0230","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s40262-013-0088-z","article-title":"Drug interactions with the newer antiepileptic drugs (AEDs)\u2013Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders","volume":"52","author":"Patsalos","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.yebeh.2020.107540_b0235","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","article-title":"Enzyme induction with antiepileptic drugs: cause for concern?","volume":"54","author":"Brodie","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107540_b0240","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.neuint.2017.02.002","article-title":"Post-stroke epilepsy","volume":"107","author":"Tanaka","year":"2017","journal-title":"Neurochem Int"},{"key":"10.1016\/j.yebeh.2020.107540_b0245","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12883-019-1587-9","article-title":"Comparing healthcare cost associated with the use of enzyme-inducing and non-enzyme active antiepileptic drugs in elderly patients with epilepsy in the UK: a long-term retrospective, matched cohort study","volume":"20","author":"Borghs","year":"2020","journal-title":"BMC Neurol"},{"key":"10.1016\/j.yebeh.2020.107540_b0250","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s10072-019-03913-4","article-title":"Hypertension, seizures, and epilepsy: a review on pathophysiology and management","volume":"40","author":"Gasparini","year":"2019","journal-title":"Neurol Sci"},{"key":"10.1016\/j.yebeh.2020.107540_b0255","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2015.243","article-title":"Management of psychiatric and neurological comorbidities in epilepsy","volume":"12","author":"Kanner","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.yebeh.2020.107540_b0260","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1528-1157.1999.tb00712.x","article-title":"Lamotrigine associated with insomnia","volume":"40","author":"Sadler","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107540_b0265","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/ane.13230","article-title":"Lacosamide in patients with epilepsy of cerebrovascular etiology","volume":"141","author":"Rosenow","year":"2020","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2020.107540_b0270","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.yebeh.2016.09.033","article-title":"NEOPLASM study: real-life use of lacosamide in patients with brain tumor-related epilepsy","volume":"65","author":"Villanueva","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107540_b0275","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.yebeh.2017.05.031","article-title":"Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: a prospective explorative study with a historical control group","volume":"73","author":"Maschio","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107540_b0280","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/ane.12809","article-title":"Outcome of cancer-related seizures in patients treated with lacosamide","volume":"137","author":"Toledo","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2020.107540_b0285","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/epi.16486","article-title":"Effectiveness and tolerability of lacosamide as add-on therapy in patients with brain tumor-related epilepsy: results from a prospective, noninterventional study in European clinical practice (VIBES)","volume":"61","author":"Rud\u00e0","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107540_b0290","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/ane.13162","article-title":"Clinical outcomes of eslicarbazepine acetate monotherapy for focal-onset seizures: a multicenter audit","volume":"140","author":"Gir\u00e1ldez","year":"2019","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2020.107540_b0295","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/ejp.1192","article-title":"Assessment of efficacy and safety of eslicarbazepine acetate for the treatment of trigeminal neuralgia","volume":"22","author":"Sanchez-Larsen","year":"2018","journal-title":"Eur J Pain"},{"key":"10.1016\/j.yebeh.2020.107540_b0300","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/head.12781","article-title":"The use of antiepileptics in migraine prophylaxis","volume":"56","author":"Bagnato","year":"2016","journal-title":"Headache"},{"key":"10.1016\/j.yebeh.2020.107540_b0305","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/WNF.0b013e318225140c","article-title":"Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial","volume":"34","author":"Mohammadianinejad","year":"2011","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.yebeh.2020.107540_b0310","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1526-4610.2009.01508.x","article-title":"Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures","volume":"49","author":"Silberstein","year":"2009","journal-title":"Headache"},{"key":"10.1016\/j.yebeh.2020.107540_b0315","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.yebeh.2017.04.003","article-title":"Psychiatric side effects and antiepileptic drugs: observations from prospective audits","volume":"71","author":"Stephen","year":"2017","journal-title":"Epilepsy Behav"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505020307204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505020307204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:37:32Z","timestamp":1761503852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505020307204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":63,"alternative-id":["S1525505020307204"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.107540","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initiating antiepilepsy treatment: An update of expert consensus in Spain","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.107540","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107540"}}